147P - Different metastatic pattern according to the EGFR mutational status in a cohort of lung adenocarcinomas (ADCs): A single-institution report

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Alessandro Russo
Citation Annals of Oncology (2015) 26 (suppl_1): 45-47. 10.1093/annonc/mdv051
Authors A. Russo, T. Franchina, A. Picone, G. Ferraro, M. Picciotto, M. Zanghì, V. Franchina, V. Adamo
  • Department Of Human Pathology University Of Messina, Medical Oncology Unit AOOR Papardo-Piemonte, 98158 - Messina/IT



Activating mutations in the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) identify a specific subgroup of non small cell lung cancer (NSCLC) patients (pts), with peculiar clinic-pathological features. Recently, it has been supposed that EGFR mutational status may predict an increased risk of developing brain metastases (BM), with a possible differential impact among the various EGFR mutations. We therefore performed a retrospective analysis of our case series in order to evaluate the role of EGFR dysregulation on metastatic spread.


Medical records of 67 consecutive treated pts with metastatic ADCs and known EGFR mutational status, treated at our institution, were reviewed. A statistical analysis was performed. P-values <0.05 were considered statistically significant.


BM were reported in 35% of pts with EGFR activating mutations. Moreover, 28% of pts had bone metastases and 35% lung metastases. Lung metastases were more common among pts harboring exon 19 deletions (4/5 pts), whereas BM seemed equally distributed (one exon 18, two exon 19 and two exon 21). In the subgroups of EGFR wild type pts BM were present in 28%, while bone and lung metastases in 16% of pts. The difference between the incidence of BM in the two groups was not statistically significant. An interesting trend toward significance was obtained in the evaluation of the incidence of lung metastases, more elevated in EGFR mutated pts.


The biomolecular characteristics and the pathways involved in the different lung cancer subtypes may directly influence the metastases formation and evolution. This report underline the need to better define the clinical and molecular characteristics in adenocarcinoma subtype related to EGFR mutational status, to improve therapeutic choices and obtain relevant clinical results.


All authors have declared no conflicts of interest.